XLRN.XX News
Archived Headlines
- 12 US IPOs planned for the week of Sep 16 09/16/13
- US IPO Recap: Benefitfocus, six others set terms as calendar rebuilds 09/08/13
- Cancer biotech Acceleron Pharma sets terms for $65 million IPO 09/06/13
- US IPO Recap: Regado slashes valuation, three deals added to IPO pipeline 08/26/13
- US IPO Recap: Nine deals price, Intrexon and Cvent soar 08/12/13
See more
Muscular dystrophy biotech aTyr Pharma sets terms for $75 million IPO
aTyr Pharma, which is developing restorative protein therapeutics for rare muscular dystrophies, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15....read more
Muscular dystrophy biotech aTyr Pharma files for a $86 million IPO
aTyr Pharma, which is developing restorative protein therapeutics for rare muscular dystrophies, filed on Monday with the SEC to raise up to $86 million in an initial public offering. aTyr notes that September 2013 biotech Acceleron Pharma (XLRN; +128%)...read more
US IPO Recap: Blazing debuts for software trio FireEye, Rocket Fuel and Benefitfocus
Rocket Fuel and FireEye had first-day returns (93% and 80%, respectively) to match their incendiary names last week, but neither could touch Benefitfocus's 102% first-day pop, just the tenth first-day double since 2000. The three represented the most 80%+...read more
Acceleron Pharma prices upsized IPO at $15, at high end of the range
Acceleron Pharma, a clinical stage biotech developing protein therapeutics for cancer and rare diseases, raised $84 million by offering 5.6 million shares at $15, at the high end of the $13 to $15 range. The Cambridge, MA-based company had originally planned to...read more